Trav2: A G-Coupled Protein Interacting with Dopamine (G28691)

Target Name: TRAV2

NCBI ID: G28691

TRAV2

Other Name(s): TCRAV11S1 | T cell receptor alpha variable 2 | TCRAV2S1

Trav2: A G-Coupled Protein Interacting with Dopamine

Trav2 (TRAV2-S1) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the superfamily of G-coupled proteins, which are a type of transmembrane protein that consists of a catalytic domain and an extracellular region.

One of the unique features of Trav2 is its ability to interact with other proteins that are expressed in the brain, including the neurotransmitter dopamine. This interaction between Trav2 and dopamine has been shown to play a role in a variety of brain functions, including motivation, pleasure, and reward.

In addition to its role in brain function, Trav2 is also a potential drug target. Its interaction with dopamine has led to the development of several compounds that are designed to modulate dopamine activity in the brain. These compounds have been shown to have a variety of therapeutic effects, including the treatment of depression, anxiety, and addiction.

TheTrav2 gene was identified and characterized in 2008 by researchers at the University of California, San Diego. The gene is located on chromosome 12q14 and has a molecular weight of approximately 17 kDa. Trav2 is expressed in a variety of tissues and cells in the body, including the brain, heart, kidneys, and liver.

Trav2 is a member of the G-coupled protein family, which consists of a catalytic domain and an extracellular region. The catalytic domain of Trav2 contains a single transmembrane alpha-helical protein that is responsible for the protein's catalytic activity. The extracellular region of Trav2 contains a variety of transmembrane and intracellular domains that are involved in the protein's interactions with other proteins.

One of the unique features of Trav2 is its ability to interact with other proteins that are expressed in the brain, including the neurotransmitter dopamine. This interaction between Trav2 and dopamine has been shown to play a role in a variety of brain functions, including motivation, pleasure, and reward.

In addition to its role in brain function, Trav2 is also a potential drug target. Its interaction with dopamine has led to the development of several compounds that are designed to modulate dopamine activity in the brain. These compounds have been shown to have a variety of therapeutic effects, including the treatment of depression, anxiety, and addiction.

The Trav2 gene was identified and characterized in 2008 by researchers at the University of California, San Diego. The gene is located on chromosome 12q14 and has a molecular weight of approximately 17 kDa. Trav2 is expressed in a variety of tissues and cells in the body, including the brain, heart, kidneys, and liver.

In conclusion, Trav2 is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the G-coupled proteins family and has been shown to interact with the neurotransmitter dopamine. This interaction plays a role in a variety of brain functions, including motivation, pleasure, and reward. As a result, Trav2 is a potential drug target and has been the focus of research into the use of compounds to modulate dopamine activity in the brain.

Protein Name: T Cell Receptor Alpha Variable 2

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets